

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED
紛美包裝有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00468)

**(1) PUBLICATION OF UNAUDITED CONSOLIDATED MANAGEMENT
ACCOUNTS OF THE GROUP FOR THE NINE MONTHS ENDED
30 SEPTEMBER 2026 AND
(2) CONTINUED SUSPENSION OF TRADING**

INTRODUCTION

This announcement is made by Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the provisions of inside information under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

**PUBLICATION OF THE UNAUDITED CONSOLIDATED MANAGEMENT ACCOUNTS OF
THE GROUP FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2026**

In order to keep the shareholders and potential investors of the Company informed of the Group’s business operations and financial position, the Company would like to provide the shareholders and potential investors of the Company with preliminary unaudited financial information of the Group for the nine months ended 30 September 2026, which was extracted from the consolidated management accounts of the Group for the nine months ended 30 September 2026, together with the comparative figures for the corresponding period in 2025.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

	For the nine months ended 30 September	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Revenue	1,298,768	1,409,527
Cost of sales	<u>(1,120,960)</u>	<u>(1,191,771)</u>
Gross profit	<u>177,808</u>	<u>217,756</u>
Other income	30,878	37,539
Other (losses)/gains, net	(8,343)	5,821
Selling and distribution expenses	(37,495)	(44,550)
Administrative expenses	(152,992)	(119,408)
Impairment losses on financial assets, net	(11,481)	(6,215)
Finance costs	(299)	(1,420)
Share of profits of associates	<u>–</u>	<u>25,932</u>
(Loss)/Profit before tax	(1,924)	115,455
Income tax expenses	<u>14,699</u>	<u>(38,473)</u>
Profit for the period	<u><u>12,775</u></u>	<u><u>76,982</u></u>
Attributable to:		
Owners of the Company	14,223	76,982
Non-controlling interests	<u>(1,448)</u>	<u>–</u>
	<u><u>12,775</u></u>	<u><u>76,982</u></u>

	For the nine months ended	
	30 September	
	2026	2025
	<i>RMB'000</i>	<i>RMB'000</i>
	(Unaudited)	(Unaudited)
Profit for the period	<u>12,775</u>	<u>76,982</u>
Other comprehensive income:		
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:		
Currency translation differences	–	12,974
Equity investments designated at fair value through other comprehensive income: – Changes in fair value	<u>–</u>	<u>57,877</u>
Other comprehensive income for the period, net of tax	<u>–</u>	<u>70,851</u>
Total comprehensive income for the period	<u>12,775</u>	<u>147,833</u>
Attributable to:		
Owners of the Company	14,223	147,833
Non-controlling interests	<u>(1,448)</u>	<u>–</u>
	<u>12,775</u>	<u>147,833</u>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

	As at 30 September 2026 <i>RMB'000</i> (Unaudited)	As at 31 December 2025 <i>RMB'000</i> (Audited)
Non-current assets		
Property, plant and equipment	559,677	586,353
Right-of-use assets	46,548	37,875
Goodwill	47,774	47,774
Other intangible assets	2,263	3,590
Trade and bills receivables	85,676	77,379
Other receivables	98,647	97,920
Prepayments	23,841	22,918
Financial assets at fair value through profit or loss (“FVTPL”)	541,041	541,041
Financial assets at fair value through other comprehensive income (“FVTOCI”)	464,040	464,040
Deferred tax assets	72,735	54,441
Total non-current assets	<u>1,942,242</u>	<u>1,933,331</u>
Current assets		
Inventories	443,152	431,949
Trade and bills receivables	667,321	487,041
Prepayments	12,265	12,294
Other receivables	53,203	55,414
Dividend receivables	–	5,623
Financial assets at fair value through profit or loss (“FVTPL”)	54,133	–
Financial assets at fair value through other comprehensive income (“FVTOCI”)	20,543	18,297
Restricted cash	217,259	172,456
Cash and cash equivalents	137,916	461,742
Total current assets	<u>1,605,792</u>	<u>1,644,816</u>

	As at 30 September 2026 <i>RMB'000</i> (Unaudited)	As at 31 December 2025 <i>RMB'000</i> (Audited)
Current liabilities		
Deferred government grants	519	1,519
Contract liabilities	7,358	8,643
Trade and bills payables	491,822	406,440
Other payables and accruals	107,394	128,645
Income tax liabilities	24,838	27,970
Borrowings	1,226	100,819
Lease liabilities	<u>3,059</u>	<u>266</u>
Total current liabilities	<u>636,216</u>	<u>674,302</u>
Net current assets	<u>969,576</u>	<u>970,514</u>
Total assets less current liabilities	<u>2,911,818</u>	<u>2,903,845</u>
Non-current liabilities		
Deferred government grants	5,876	5,776
Lease liabilities	4,493	67
Deferred tax liabilities	<u>1,065</u>	<u>1,185</u>
Total non-current liabilities	<u>11,434</u>	<u>7,028</u>
Net assets	<u>2,900,384</u>	<u>2,896,817</u>
EQUITY		
Share capital, share premium and capital reserve	517,312	519,187
Statutory reserve	356,280	356,280
Retained earnings	2,089,702	2,082,812
Exchange reserve	<u>(62,811)</u>	<u>(62,811)</u>
Attributable to equity holders of the Company	<u>2,900,483</u>	<u>2,895,468</u>
Non-controlling interests	<u>(99)</u>	<u>1,349</u>
Total equity	<u><u>2,900,384</u></u>	<u><u>2,896,817</u></u>

The Board wishes to emphasise that the unaudited financial information set out above is subject to, among others, further review by the Company and any potential adjustments that might be proposed by the Auditors upon the completion of Investigation, and has not been reviewed by the audit committee of the Company, nor has it been reviewed, audited or approved by the Auditors. The unaudited financial information above is only based on the preliminary assessment by the Board on the unaudited consolidated management accounts of the Group for the nine months ended 30 September 2026, and is not based on any data or information that has been audited, reviewed or approved by the Auditors, the audit committee of the Company and the Company. The unaudited financial information will be subject to changes resulting from, among others, further review by the Company and any adjustments that may be made by the Auditors subject to the completion of the Investigation and auditing process. The Board cannot guarantee the unaudited financial information set out above truly reflects the financial performance and condition of the Group and such information might be misleading if any potential adjustments have not been taken into account.

Shareholders and potential investors should exercise extreme caution when considering the unaudited financial information disclosed above and when dealing in the shares of the Company.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
Greatview Aseptic Packaging Company Limited
YUAN Xunjun
Chairman and Executive Director

Beijing, the People's Republic of China, 26 October 2026

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. YUAN Xunjun and Mr. WANG Dawei; five non-executive directors, namely, Ms. WANG Ziting, Ms. WANG Yingli, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. LI Weijin; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi.